<H1>Chapter DOI: 10.1186/s12958-016-0164-y<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>26</td></tr><tr><td>Springer references</td><td>5</td></tr><tr><td>Non Springer references</td><td>21</td></tr><tr><td>BibStructured Count</td><td width="10%">23</td></tr><tr><td>BibUnstructured Count</td><td width="10%">3</td></tr><tr><td>DOI already available in SpringerLink</td><td>21</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3:161&#8211;71.</td><td><a href=http://dx.doi.org/10.2165/00024677-200403030-00004>10.2165/00024677-200403030-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>van</span> <span style='background:#BCBCBC'>Wely</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kwan</span> <span style='background:#DDDDDD'>I</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Burt</span> <span style='background:#DDDDDD'>AL</span></span>, et al.</aug> <span style='background:#CCCCFF'>Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles</span>. <span style='background:#CCFF99'>Cochrane Database Syst Rev</span>. <span style='background:#66FF66'>2011</span>;<span style='background:#FFFF0F'>(2):CD005354</span>.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/14651858.CD005354.pub2>10.1002/14651858.CD005354.pub2</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report. Gynecol Endocrinol. 2000;14:149&#8211;52.</td><td><a href=http://dx.doi.org/10.3109/09513590009167674>10.3109/09513590009167674</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>European Medicines Agency (EMA)</span>. <span style='background:#FFD9B3'>Ovaleap (follitropin alfa) [assessment report]</span>. <span style='background:#C0FFC0'>London, UK</span>: EMA; July 31, 2013. <span style='background:#FF3300'>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002608/WC500152908.pdf</span> (<span style='background:#66FF66'>2013</span>). Accessed 10 Mar 2016.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Weise M, Bielsky MC, De Smet K, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29:690&#8211;3.</td><td><a href=http://dx.doi.org/10.1038/nbt.1936>10.1038/nbt.1936</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibBook</td><td>Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH). London: EMA; 2011.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Lammerich A, Mueller A, Bias P. Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f&#174; in healthy women after follicle-stimulating hormone downregulation. Reprod Biol Endocrinol. 2015;13:130.</td><td><a href=http://dx.doi.org/10.1186/s12958-015-0124-y>10.1186/s12958-015-0124-y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Lammerich A, Bias P, Gertz B. Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women. Int J Women&#8217;s Health. 2015;7:707&#8211;16.</td><td><a href=http://dx.doi.org/10.2147/IJWH.S83418>10.2147/IJWH.S83418</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Strowitzki T, Kuczynski W, Mueller A, Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap&#174; (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol. 2016;14:1.</td><td><a href=http://dx.doi.org/10.1186/s12958-015-0135-8>10.1186/s12958-015-0135-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Scott L, Alvero R, Leondires M, Miller B. The morphology of human pronuclear embryos is positively related to blastocyst development and implantation. Hum Reprod. 2000;15:2394&#8211;403.</td><td><a href=http://dx.doi.org/10.1093/humrep/15.11.2394>10.1093/humrep/15.11.2394</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112&#8211;20.</td><td><a href=http://dx.doi.org/10.1016/j.fertnstert.2005.07.1292>10.1016/j.fertnstert.2005.07.1292</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249&#8211;61.</td><td><a href=http://dx.doi.org/10.1016/S0015-0282(16)55188-7>10.1016/S0015-0282(16)55188-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Somkuti SG, Schertz JC, Moore M, Ferrande L, Kelly E. Patient experience with follitropin alfa prefilled pen versus previously used injectable gonadotropins for ovulation induction in oligoanovulatory women. Curr Med Res Opin. 2006;22:1981&#8211;96.</td><td><a href=http://dx.doi.org/10.1185/030079906X132604>10.1185/030079906X132604</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zou</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mueller</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gertz</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Weiss</span> <span style='background:#DDDDDD'>H</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Liu</span> <span style='background:#DDDDDD'>P.</span></span>, <span style='background:#BDBAD6'>Immunogenicity assessment of Ovaleap&#174; (XM17) recombinant human follicle-stimulating hormone in infertile women undergoing assisted reproductive technology (ART). Presented at the 17th World Congress of Gynecological Endocrinology, March 2&#8211;5,</span></aug> <span style='background:#66FF66'>2016</span>, <span style='background:#C0FFC0'>Florence, Italy</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15</td><td>BibArticle</td><td>European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0015-0282(02)03250-8>10.1016/S0015-0282(02)03250-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2001;76:543&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0015-0282(01)01973-2>10.1016/S0015-0282(01)01973-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Frydman R, Howles CM, Truong F. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F&#174;) with highly purified urinary FSH (Metrodin&#174; HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. Hum Reprod. 2000;15:520&#8211;5.</td><td><a href=http://dx.doi.org/10.1093/humrep/15.3.520>10.1093/humrep/15.3.520</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Schats R, Sutter PD, Bassil S, Kremer JA, Tournaye H, Donnez J. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. Hum Reprod. 2000;15:1691&#8211;7.</td><td><a href=http://dx.doi.org/10.1093/humrep/15.8.1691>10.1093/humrep/15.8.1691</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21:3217&#8211;27.</td><td><a href=http://dx.doi.org/10.1093/humrep/del284>10.1093/humrep/del284</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Imthurn B, Rettenbacher M, Bemfola Study Group. A phase III assessor-blinded randomised multi-centre study to compare efficacy and safety of two r-hFSH formulations (AFOLIA [Bemfola&#174;] vs Gonal-f&#174;) in women for assisted reproductive treatment [abstract]. Hum Reprod. 2013;28 suppl 1:i45.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Utsunomiya T, Tanaka A, Tatsumi K, Ezcurra D. A questionnaire-based survey to assess patient satisfaction, ease-of-learning, ease-of-use, injection site pain and overall patient satisfaction of the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen compared with other systems of gonadotrophin administration. Reprod Biol Endocrinol. 2012;10:93.</td><td><a href=http://dx.doi.org/10.1186/1477-7827-10-93>10.1186/1477-7827-10-93</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Welcker JT, Nawroth F, Bilger W. Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study. Reprod Biol Endocrinol. 2010;8:111.</td><td><a href=http://dx.doi.org/10.1186/1477-7827-8-111>10.1186/1477-7827-8-111</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Rabinson J, Ashkenazi J, Homburg R, Meltcer S, Anteby EY, Orvieto R. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists. Fertil Steril. 2009;91:1473&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.fertnstert.2008.07.1725>10.1016/j.fertnstert.2008.07.1725</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Eppsteiner EE, Sparks AE, Liu D, Van Voorhis BJ. Change in oocyte yield in repeated in vitro fertilization cycles: effect of ovarian reserve. Fertil Steril. 2014;101:399&#8211;402.</td><td><a href=http://dx.doi.org/10.1016/j.fertnstert.2013.10.049>10.1016/j.fertnstert.2013.10.049</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Landfeldt E, Jablonowska B, Norlander E, et al. Patient preferences for characteristics differentiating ovarian stimulation treatments. Hum Reprod. 2012;27:760&#8211;9.</td><td><a href=http://dx.doi.org/10.1093/humrep/der449>10.1093/humrep/der449</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Boivin J, Domar AD, Shapiro DB, Wischmann TH, Fauser BC, Verhaak C. Tackling burden in ART: an integrated approach for medical staff. Hum Reprod. 2012;27:941&#8211;50.</td><td><a href=http://dx.doi.org/10.1093/humrep/der467>10.1093/humrep/der467</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>